Home > Boards > US OTC > Biotechs > Ampio Pharmaceuticals, Inc (AMPE)

BarChart BUY 64% https://www.barchart.com/stocks/quotes/ampe/opinion

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
0210 Member Profile
Member Level 
Followed By 64
Posts 3,884
Boards Moderated 0
Alias Born 11/12/10
160x600 placeholder
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled PR Newswire (US) - 1/14/2021 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:59:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:58:29 PM
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients PR Newswire (US) - 1/4/2021 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/29/2020 4:18:32 PM
Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatmen... PR Newswire (US) - 12/29/2020 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:41:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:39:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:37:51 PM
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion PR Newswire (US) - 12/17/2020 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 4:02:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:25:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:24:03 PM
Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug,... PR Newswire (US) - 12/10/2020 9:15:00 AM
Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020 PR Newswire (US) - 12/8/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 12/2/2020 9:15:00 AM
Ampio Updates Regulatory and Clinical Trial Events PR Newswire (US) - 11/25/2020 9:15:00 AM
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress PR Newswire (US) - 11/17/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 11/10/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:02:00 PM
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/5/2020 3:45:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2020 9:32:51 AM
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th PR Newswire (US) - 11/2/2020 9:15:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/30/2020 11:21:24 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/30/2020 11:13:06 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences